176 related articles for article (PubMed ID: 22400986)
41. Use of rodent data for cancer risk assessment of smokeless tobacco in the regulatory context.
Nilsson R
Regul Toxicol Pharmacol; 2017 Aug; 88():338-348. PubMed ID: 28625913
[TBL] [Abstract][Full Text] [Related]
42. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch.
Stepanov I; Biener L; Knezevich A; Nyman AL; Bliss R; Jensen J; Hecht SS; Hatsukami DK
Nicotine Tob Res; 2012 Mar; 14(3):274-81. PubMed ID: 22039075
[TBL] [Abstract][Full Text] [Related]
43. Mutagenicity of coal-dust and smokeless-tobacco extracts in Salmonella typhimurium strains with differing levels of O-acetyltransferase activities.
Stamm SC; Zhong BZ; Whong WZ; Ong T
Mutat Res; 1994 Jun; 321(4):253-64. PubMed ID: 7515163
[TBL] [Abstract][Full Text] [Related]
44. Assessment of a 72-hour repeated exposure to Swedish snus extract and total particulate matter from 3R4F cigarette smoke on gingival organotypic cultures.
Zanetti F; Sewer A; Titz B; Schlage WK; Iskandar AR; Kondylis A; Leroy P; Guedj E; Trivedi K; Elamin A; Martin F; Frentzel S; Ivanov NV; Peitsch MC; Hoeng J
Food Chem Toxicol; 2019 Mar; 125():252-270. PubMed ID: 30610935
[TBL] [Abstract][Full Text] [Related]
45. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007.
Borgerding MF; Bodnar JA; Curtin GM; Swauger JE
Regul Toxicol Pharmacol; 2012 Dec; 64(3):367-87. PubMed ID: 23000415
[TBL] [Abstract][Full Text] [Related]
46. Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs).
Back S; Masser AE; Rutqvist LE; Lindholm J
BMC Chem; 2023 Mar; 17(1):9. PubMed ID: 36869349
[TBL] [Abstract][Full Text] [Related]
47. Chemical profile of two types of oral snuff tobacco.
Brunnemann KD; Qi J; Hoffmann D
Food Chem Toxicol; 2002 Nov; 40(11):1699-703. PubMed ID: 12176096
[TBL] [Abstract][Full Text] [Related]
48. Method development and validation of dissolution testing for nicotine release from smokeless tobacco products using flow-through cell apparatus and UPLC-PDA.
Miller JH; Danielson T; Pithawalla YB; Brown AP; Wilkinson C; Wagner K; Aldeek F
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1141():122012. PubMed ID: 32065955
[TBL] [Abstract][Full Text] [Related]
49. Is Swedish snus associated with smoking initiation or smoking cessation?
Furberg H; Bulik CM; Lerman C; Lichtenstein P; Pedersen NL; Sullivan PF
Tob Control; 2005 Dec; 14(6):422-4. PubMed ID: 16319367
[TBL] [Abstract][Full Text] [Related]
50. Levels of toxins in oral tobacco products in the UK.
McNeill A; Bedi R; Islam S; Alkhatib MN; West R
Tob Control; 2006 Feb; 15(1):64-7. PubMed ID: 16436408
[TBL] [Abstract][Full Text] [Related]
51. Screening for agents inhibiting the mutagenicity of extracts and constituents of tobacco products.
Romert L; Jansson T; Curvall M; Jenssen D
Mutat Res; 1994 Aug; 322(2):97-110. PubMed ID: 7519327
[TBL] [Abstract][Full Text] [Related]
52. Effect of smokeless tobacco (snus) on smoking and public health in Sweden.
Foulds J; Ramstrom L; Burke M; Fagerström K
Tob Control; 2003 Dec; 12(4):349-59. PubMed ID: 14660766
[TBL] [Abstract][Full Text] [Related]
53. The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus).
Alizadehgharib S; Lehrkinder A; Alshabeeb A; Östberg AK; Lingström P
Eur J Oral Sci; 2022 Aug; 130(4):e12885. PubMed ID: 35853092
[TBL] [Abstract][Full Text] [Related]
54. Oral cancer after using Swedish snus (smokeless tobacco) for 70 years - a case report.
Zatterstrom UK; Svensson M; Sand L; Nordgren H; Hirsch JM
Oral Dis; 2004 Jan; 10(1):50-3. PubMed ID: 14996295
[TBL] [Abstract][Full Text] [Related]
55. Smokeless tobacco and some tobacco-specific N-nitrosamines.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
IARC Monogr Eval Carcinog Risks Hum; 2007; 89():1-592. PubMed ID: 18335640
[No Abstract] [Full Text] [Related]
56. The composition of contemporary American and Swedish smokeless tobacco products.
McAdam KG; Kimpton H; Faizi A; Porter A; Rodu B
BMC Chem; 2019 Dec; 13(1):31. PubMed ID: 31384779
[TBL] [Abstract][Full Text] [Related]
57. Nonsmokers' responses to new warning labels on smokeless tobacco and electronic cigarettes: an experimental study.
Popova L; Ling PM
BMC Public Health; 2014 Sep; 14():997. PubMed ID: 25253295
[TBL] [Abstract][Full Text] [Related]
58. Enamel staining with e-cigarettes, tobacco heating products and modern oral nicotine products compared with cigarettes and snus: An in vitro study.
Dalrymple A; Bean EJ; Badrock TC; Weidman RA; Thissen J; Coburn S; Murphy J
Am J Dent; 2021 Feb; 34(1):3-9. PubMed ID: 33544982
[TBL] [Abstract][Full Text] [Related]
59. A cessation program for snuff-dippers with long-term, extensive exposure to Swedish moist snuff: A 1-year follow-up study.
Wallström M; Bolinder G; Hassèus B; Hirsch JM
Acta Odontol Scand; 2010 Nov; 68(6):377-84. PubMed ID: 20831357
[TBL] [Abstract][Full Text] [Related]
60. Nicotine Content in Swedish-Type Snus Sold in Norway From 2005 to 2020.
Vedøy TF; Lund KE
Nicotine Tob Res; 2022 Jun; 24(7):1130-1133. PubMed ID: 35022786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
